Sun Pharma recalls over 5.2k units of testosterone cypionate injections from US

Image
Press Trust of India New Delhi
Last Updated : Aug 05 2018 | 10:10 AM IST

The US arm of the domestic drug major Sun Pharmaceutical Industries is recalling over 5.2 thousand units of testosterone cypionate injections from the American market, the latest enforcement report of the US health regulator has said.

Sun Pharmaceutical Industries Inc is recalling 5,215 units of 10 mL vials testosterone cypionate injections in the strength of 200 mg/mL, on account of "presence of particulate matter: organic and inorganic compounds detected in vials of product," the report said.

The injections were manufactured by Sun Pharmaceutical Industries at its Halol facility, it added.

As per the report by the United States Food and Drug Administration (USFDA), the ongoing voluntary nationwide recall is a class II recall.

According to the US health regulator, a class II recall is initiated in a situation "in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 05 2018 | 10:10 AM IST

Next Story